mRNA Technology Newsletter
Issue #61November 2, 20267 studies

First mRNA cancer vaccine cuts melanoma recurrence risk by 42% in Phase III trial

An mRNA cancer vaccine just cleared its biggest test yet.

The results from the first successful Phase III trial of a personalized mRNA cancer vaccine landed this week, and the field of RNA medicine had a lot more to say alongside it.

๐ŸŽฏ The mRNA Cancer Vaccine Era Has a Phase III Win

  • Adding the personalized mRNA vaccine intismeran autogene to the checkpoint drug pembrolizumab after melanoma surgery reduced the risk of disease recurrence or death by 42% compared to pembrolizumab alone, according to results from the Phase III INTerpath-001 trial presented at ESMO 2026.
  • The vaccine is individualized โ€” it's designed around each patient's own tumor mutations, meaning it targets neoantigens specific to that person's cancer.
  • This is a Phase III result, not a pilot. That distinction matters: earlier-phase wins in cancer vaccines have stalled before, and this one held up at scale.

Why it matters: Personalized mRNA cancer vaccines have been a compelling idea for years. A Phase III win in melanoma is the clearest evidence yet that the concept translates beyond the lab โ€” and it puts pressure on every other tumor type to follow.

๐Ÿฅ‡ Top 1% journal ๐Ÿ”— Cancer discovery Journal Article ๐Ÿ—“๏ธ Oct 26

Key Findings

๐Ÿฆ Bird Flu Vaccine Works Better With a Longer Wait Between Doses

  • In a Phase I trial of 212 healthy adults, an H5N1 self-amplifying mRNA vaccine (ARCT-2304) given on an 8-week schedule produced stronger and more durable antibody responses than the same vaccine given 4 weeks apart โ€” with neutralizing antibodies still significantly elevated 6-7 months after the second dose.
  • The vaccine encodes both hemagglutinin and neuraminidase proteins, and also triggered T-cell responses. Side effects were mostly mild to moderate and transient.
๐Ÿ’ก Spacing doses further apart meaningfully extended H5N1 vaccine protection in adults.
๐Ÿฅˆ Top 2% journal ๐Ÿ”— Nature communications Randomized Controlled Trial ๐Ÿ—“๏ธ Oct 26

๐Ÿ“ Where mRNA Goes After a Vaccine Shot Is More Complicated Than Expected

  • A rat study tracking three common lipid nanoparticle formulations after subcutaneous injection found that mRNA components and lipid components don't always travel together through the lymphatic system โ€” lipid components showed up in thoracic lymph at 3-4x higher rates than the mRNA they were supposed to carry.
  • Concentrations of all components were 10 to 1,000-fold higher in thoracic lymph than in blood after subcutaneous injection, suggesting the lymphatic route is the primary highway โ€” but mRNA appears to get lost along the way.
๐Ÿ’ก mRNA and its lipid carrier may separate in transit, complicating delivery efficiency assumptions.
๐Ÿ”— J Control Release Journal Article ๐Ÿ—“๏ธ Oct 26

๐Ÿงฌ A Modified Nucleoside Boosted Antigen Output in Immune Cells Up to 20-Fold

  • Swapping standard uridine for a chemically modified version (N1-methylpseudouridine) in mRNA encoding tumor antigens increased protein production in human dendritic cells by up to 20-fold compared to unmodified mRNA.
  • Those antigen-loaded dendritic cells then successfully primed cancer-targeting T cells from healthy donor blood, with the resulting T cells showing strong killing activity against tumor cell lines expressing the target antigens.
๐Ÿ’ก A single chemical tweak to mRNA dramatically amplified antigen output in human immune cells.
Top 20% journal ๐Ÿ”— International journal of molecular sciences Journal Article ๐Ÿ—“๏ธ Oct 27

๐Ÿ’‰ Moderna and Pfizer Vaccines Differ in How Quickly mRNA Breaks Down in Blood

  • Analyzing serial blood samples from 73 vaccinated humans, researchers found that intact vaccine mRNA declined about 2-fold faster after Moderna mRNA-1273 than after Pfizer-BioNTech BNT162b2 vaccination.
  • The lipid carrier for BNT162b2 persisted longer than its associated intact mRNA, while Moderna's SM-102 lipid tracked more closely with mRNA decay โ€” a platform-specific difference with potential implications for how long each vaccine produces spike protein.
๐Ÿ’ก The two leading COVID vaccines break down at measurably different rates in human blood.
๐Ÿฅˆ Top 2% journal ๐Ÿ”— ACS nano Journal Article ๐Ÿ—“๏ธ Oct 27

๐Ÿค– An AI Tool Improved mRNA Stability Prediction by 13% โ€” and Redesigned a Vaccine Sequence

  • RNASTOP, a deep learning framework combining neural networks with heuristic search, outperformed the previous top model on a standard mRNA degradation benchmark by 13% in accuracy.
  • Applied to codon optimization for a varicella-zoster virus vaccine sequence, it reduced the minimum free energy of the mRNA structure by 75.73% while maintaining translation efficiency โ€” a design move that could extend shelf life and potency.
๐Ÿ’ก AI-guided mRNA redesign cut structural instability by nearly three-quarters in a vaccine sequence.
๐Ÿฅˆ Top 2% journal ๐Ÿ”— Genomics, proteomics & bioinformatics Journal Article ๐Ÿ—“๏ธ Oct 26

๐Ÿงช Exosome-Mimicking Nanoparticles Delivered Gene Therapy to Pancreatic Tumors Without Liver Buildup

  • Researchers tested an experimental combination treatment in mouse models of pancreatic cancer.
  • In mouse models of pancreatic ductal adenocarcinoma โ€” one of the hardest-to-treat solid tumors โ€” the particles accumulated preferentially in tumors rather than the liver and drove significant tumor regression with repeated intravenous dosing.
๐Ÿ’ก Exosome-mimicking particles redirected gene therapy away from the liver in a tough tumor model.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Advanced healthcare materials Journal Article ๐Ÿ—“๏ธ Oct 27

Implications

The Phase III melanoma result reframes personalized mRNA cancer vaccines from promising to proven โ€” at least in one tumor type. The open question now is whether the same approach holds in cancers with fewer mutations and colder immune environments, where neoantigens are harder to find and T cells harder to activate.

Studies in this issue

Primary sources used for this newsletter.

  1. First mRNA Cancer Vaccine Shows Success in Final Phase Trial
    main storyCancer discovery2026-10-26PMID 42929716
  2. Predicting and Improving mRNA Chemical Stability Using Deep Learning
    key findingGenomics, proteomics & bioinformatics2026-10-26PMID 42928593
  3. How mRNA-lipid nanoparticles enter the lymph system and spread through the body after injection into veins or under the skin
    key findingJournal of controlled release : official journal of the Controlled Release Society2026-10-26PMID 42933668
  4. Modified mRNA in Immune Cells Helps Produce Effective Cancer-Fighting T Cells
    key findingInternational journal of molecular sciences2026-10-27PMID 42941960